Thromb Haemost 1981; 45(03): 255-256
DOI: 10.1055/s-0038-1650182
Original Article
Schattauer GmbH Stuttgart

Successful Treatment of Raynaud's Syndrome with Prostacyclin

J J F Belch
1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
,
P Newman
2   The Department of Clinical Physics and Bioengineering, West of Scotland Health Board, U. K.
,
J K Drury
3   The Department of Vascular Surgery, Glasgow Royal Infirmary, Southern General Hospital, Glasgow, U. K.
,
H Capell
1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
,
P Leiberman
3   The Department of Vascular Surgery, Glasgow Royal Infirmary, Southern General Hospital, Glasgow, U. K.
,
W B James
4   The Department of Radiology, Southern General Hospital, Glasgow, U. K.
,
C D Forbes
1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
,
C R M Prentice
1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
› Author Affiliations
Further Information

Publication History

Received 10 February 1981

Accepted 03 April 1981

Publication Date:
06 July 2018 (online)

Summary

There is evidence to suggest that platelet activation occurs in Raynaud’s syndrome. We evaluated the effect of prostacyclin (PGI2) a potent antiplatelet and vasodilator agent in 5 female patients with Raynaud’s syndrome. Outpatient visits were made at weekly intervals for 4 weeks. At the first visit buffer solution (Wellcome Laboratories) was infused intravenously for 5 hrs, thereafter three five hr infusions of PGI2 at a peak dose of 10 ng/ Kg/min were given. Six weeks after the infusions patients were reviewed. Symptomatic improvement, including healing of ischaemic ulcers, occurred in 4 out of 5 patients. Thermography confirmed an increase in hand temperature after PCI2. Subjective and objective improvement has persisted for at least 6 weeks after the last treatment.

 
  • References

  • 1 Dodds AJ, O’Reilly MJ G, Yates CJ P, Cotton LT, Flute PT, Dormandy JA. Haemorrheological response to plasma exchange in Raynaud’s syndrome. Br Med J 1979; 02: 1186-1187
  • 2 O’Reilly MJ G, Zahavi J, Dubiel M, Cotton LT, Kakkar VV. Plasmapheresis and platelet function in Raynaud’s phenomenon. Thromb Haemostas 1979; 42: 338-344
  • 3 James PB, Galloway RW. Brachial arteriography in vibration induced white finger. In: Taylor W. Ed. The Vibration Syndrome. Academic Press; 1974: 195-204
  • 4 Ring EF J, Bacon PA. Quantitative thermographic assessment of Inositol Nicotinate therapy in Raynaud’s phenomenon. J Int Med Res 1977; 05: 217-222
  • 5 Acciarri L, Camevale F, Della SelvaA. Thermography in the hand angiopathy from vibrating tools. Acta Therm 1976; 01: 18-28
  • 6 Ludlam CA, Moore S, Bolton AE, Pepper DS, Cash JD. The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res 1975; 06: 543-548
  • 7 Crawford DG, Freisen DD, Tomlinson-Keasey C. Effects of cognitively induced anxiety on hand temperature. Biofeedback and Self-Regal 1977; 02: 993-998
  • 8 Carter SA. Voluntary increase in finger temperature in man in a cooling environment. Canad J Physiol Pharmacol 1978; 56: 993-998
  • 9 Jirak Z, Jokl M, Stverak J, Pechlat R, Coufalova H. Correction factors in skin temperature measurement. J Appl Physiol 1975; 33: 752-756
  • 10 Chucker F, Fowler RC, Motomiya T, Singh B, Burley W. Induced temperature transients in Raynaud’s disease measured by thermography. Angiology 1971; 22: 580-593
  • 11 Chang CP. Cold water immersion test in patients with vibration disease. Jpn J Ind Health 1976; 18: 453-463
  • 12 Hildebrant G. Circadian variations of thermoregulatory response in man. Chronobiol 1974; 234-240